{"id":831184,"date":"2025-03-28T11:00:19","date_gmt":"2025-03-28T15:00:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/"},"modified":"2025-03-28T11:00:19","modified_gmt":"2025-03-28T15:00:19","slug":"investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/","title":{"rendered":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, March  28, 2025  (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc.\u00a0(\u201cActinium\u201d or the \u201cCompany\u201d) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and\/or misleading statements, and\/or failed to disclose material adverse facts, including allegations that: (i) Actinium \u201crepeatedly touted the Sierra Trial\u2019s positive DCR data while downplaying the study\u2019s failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial\u2019s poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the BLA.\u201d<\/p>\n<p align=\"justify\">If you bought shares of Actinium between <strong>October 31, 2022 and August 2, 2024<\/strong>, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rYduTJDYdm5IJfuMNot9tcPmY_L_0Cps0NIlu7xKwtPjZjJhMczGpVbLufNKnhmve-IF9l7PKzxmy2AlID5pC2xMPEZ666rwltPutk_D7B0=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a>, by toll-free telephone at (888) 508-6832 or you may visit the firm\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A7YhmOYqwINK0TXTCUwcEGAyWh0Oeb9R93PQwUyP_PXliqGiKiXgN8moTr-eoh_22sQ0COf_NzlTp0OCJQVpbmC8gfPlfcKhWguO2q6I1_PLiyqGNC879cz8864g1jkbg4ubGWFnQ1cEUWLTjirHIlbnoW0CXrpSRssKTYIKPHY=\" rel=\"nofollow\" target=\"_blank\"><u>www.holzerlaw.com\/case\/actinium-pharmaceuticals\/<\/u><\/a> to learn more.<\/p>\n<p align=\"justify\">\n        <strong>The deadline to ask the court to be appointed lead plaintiff in the case is May 26, 2025.<\/strong>\n      <\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website,\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A7YhmOYqwINK0TXTCUwcEGsWynyC6Ez8EEGaxGLhcSqzyPvlC-4cTZolDIFlb9TNuUnT5zlXiV5mEJknwmThRLVxV7a9AIZisYyFEeVs-M8=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com<\/a>,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free) <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rYduTJDYdm5IJfuMNot9tcPmY_L_0Cps0NIlu7xKwtOxiDYer39lfXNXR4wTFSJeIZfQyDenvzC9o7eyqP0xxXDEeLAY93uasHINws292Fw=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDIxMjgxZGYtZWUxNC00YjFjLTk4YTUtNThmYTYyMjYxZTFjLTExOTIzMzYtMjAyNS0wMy0yOC1lbg==\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc.\u00a0(\u201cActinium\u201d or the \u201cCompany\u201d) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and\/or misleading statements, and\/or failed to disclose material adverse facts, including allegations that: (i) Actinium \u201crepeatedly touted the Sierra Trial\u2019s positive DCR data while downplaying the study\u2019s failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial\u2019s poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc.\u00a0(\u201cActinium\u201d or the \u201cCompany\u201d) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and\/or misleading statements, and\/or failed to disclose material adverse facts, including allegations that: (i) Actinium \u201crepeatedly touted the Sierra Trial\u2019s positive DCR data while downplaying the study\u2019s failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial\u2019s poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the &hellip; Continue reading &quot;INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T15:00:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm\",\"datePublished\":\"2025-03-28T15:00:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/\"},\"wordCount\":340,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/\",\"name\":\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=\",\"datePublished\":\"2025-03-28T15:00:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk","og_description":"ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc.\u00a0(\u201cActinium\u201d or the \u201cCompany\u201d) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and\/or misleading statements, and\/or failed to disclose material adverse facts, including allegations that: (i) Actinium \u201crepeatedly touted the Sierra Trial\u2019s positive DCR data while downplaying the study\u2019s failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial\u2019s poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the &hellip; Continue reading \"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-28T15:00:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm","datePublished":"2025-03-28T15:00:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/"},"wordCount":340,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/","name":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=","datePublished":"2025-03-28T15:00:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjg0NCM2ODM5ODExIzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-actinium-pharmaceuticals-inc-atnm-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-f\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}